CareDx vs Fulgent Genetics
CDNA and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDNA and FLGT compare
CareDx is the larger company, worth 6.0 times as much as Fulgent Genetics ($4.3B against $707M).
CareDx grew revenue faster over the last twelve months (38.9% versus 4.7% for Fulgent Genetics).
CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with −27.5% at Fulgent Genetics.
CareDx scores higher on the StockData Score (12 against 8 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDNA | FLGT |
|---|---|---|
| Size and price | ||
| Market cap | $4.3B | $707M |
| Share price | $81.17 | $25.70 |
| Change, 1 year | 386% | −5.4% |
| Change, 5 years | 88.7% | −72.7% |
| Beta (5Y) | 1.52 | 0.90 |
| Employees | 765 | 1,300 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 34.0× | – |
| P/S | 8.6× | 2.1× (better) |
| P/B | 9.1× | 0.7× (better) |
| EV/EBITDA | 29.9× | – |
| FCF yield | – | −0.20% |
| Fair value | $66.02 | $50.48 |
| Margin of safety | −22.9% | 49.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 38.9% (better) | 4.7% |
| Revenue growth, 5Y average | 14.6% (better) | −5.2% |
| Net income growth (TTM) | 82.6% | – |
| Profitability | ||
| Gross margin | – | 33.8% |
| Operating margin | 23.4% (better) | −39.2% |
| Net margin | 25.9% (better) | −27.5% |
| FCF margin | – | −0.42% |
| Return on equity | 33.0% (better) | −8.6% |
| Return on invested capital | 69.8% (better) | −12.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Interest coverage | – | −1307.9× |
| Current ratio | 2.31 | 5.34 (better) |
| Altman Z-score | 15.36 (better) | 5.36 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 9.1% |
| Shareholder yield | 0.00% | 9.1% (better) |
| Ownership | ||
| Held by institutions | 102% | 57.0% |
| Held by insiders | 4.8% | 39.5% |
| Insider net buying, 12 months | −$18.1M | −$286K (better) |
| Short interest, % of float | 14.4% | 12.1% |
Go deeper
- CDNA stock overview
- CDNA income statement
- CDNA valuation and score
- FLGT stock overview
- FLGT income statement
- FLGT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.